Salarius Historical Income Statement

SLRX Stock

USD 1.43 0.02 1.38%

Historical analysis of Salarius Pharmaceuticals income statement accounts such as Other Operating Expenses of 12.2 K, Research Development of 6.8 K, Total Operating Expenses of 12.2 K or Non Operating Income Net Other of 667.5 K can show how well Salarius Pharmaceuticals performed in making a profits. Evaluating Salarius Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Salarius Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Salarius Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Salarius Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Salarius Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Salarius Stock please use our How to Invest in Salarius Pharmaceuticals guide.

About Salarius Income Statement Analysis

Salarius Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Salarius Pharmaceuticals shareholders. The income statement also shows Salarius investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Salarius Pharmaceuticals Income Statement Chart

At this time, Salarius Pharmaceuticals' Interest Income is fairly stable compared to the past year. Interest Expense is likely to rise to about 281.6 K in 2024, whereas Depreciation And Amortization is likely to drop 9,548 in 2024.

Selling General Administrative Research Development Total Operating Expenses Income Before Tax

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Salarius Pharmaceuticals income statement and is an important metric when analyzing Salarius Pharmaceuticals profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Most accounts from Salarius Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Salarius Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Salarius Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Salarius Stock please use our How to Invest in Salarius Pharmaceuticals guide.At this time, Salarius Pharmaceuticals' Interest Income is fairly stable compared to the past year. Interest Expense is likely to rise to about 281.6 K in 2024, whereas Depreciation And Amortization is likely to drop 9,548 in 2024.

	2023	2024 (projected)
Depreciation And Amortization	10.1K	9.5K
Interest Income	355.8K	441.7K

Depreciation And Amortization Interest Income

Salarius Pharmaceuticals income statement Correlations

	Interest Income	Depreciation And Amortization	Selling General Administrative	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Non Operating Income Net Other	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Interest Income	Discontinued Operations	Total Revenue	Gross Profit	Cost Of Revenue	Reconciled Depreciation	Extraordinary Items	Selling And Marketing Expenses
Interest Income		0.19	-0.36	-0.4	0.42	0.51	0.42	-0.42	0.42	-0.4	0.46	0.62	0.92	0.48	-0.9	-0.46	-0.17	0.35	0.44	-0.52	-0.35	-0.17	-0.17
Depreciation And Amortization	0.19		0.49	0.54	-0.46	-0.38	-0.46	0.52	-0.45	0.52	-0.44	0.79	0.21	-0.44	-0.22	0.0	0.29	0.01	-0.06	0.33	0.45	0.29	0.29
Selling General Administrative	-0.36	0.49		0.97	-0.91	-0.73	-0.91	0.85	-0.91	0.97	-0.9	-0.11	-0.11	-0.9	0.06	0.46	0.67	-0.06	-0.25	0.92	0.94	0.67	0.67
Other Operating Expenses	-0.4	0.54	0.97		-0.98	-0.8	-0.98	0.96	-0.97	1.0	-0.97	-0.03	-0.17	-0.97	0.1	0.39	0.71	-0.11	-0.28	0.84	0.85	0.71	0.71
Operating Income	0.42	-0.46	-0.91	-0.98		0.86	1.0	-0.97	1.0	-0.98	1.0	0.07	0.21	1.0	-0.13	-0.44	-0.66	0.25	0.4	-0.79	-0.78	-0.66	-0.66
Net Income From Continuing Ops	0.51	-0.38	-0.73	-0.8	0.86		0.86	-0.8	0.86	-0.79	0.87	0.11	0.47	0.88	-0.37	-0.77	-0.23	0.63	0.74	-0.75	-0.69	-0.23	-0.23
Ebit	0.42	-0.46	-0.91	-0.98	1.0	0.86		-0.97	1.0	-0.98	1.0	0.07	0.21	1.0	-0.13	-0.45	-0.66	0.26	0.4	-0.79	-0.79	-0.66	-0.66
Research Development	-0.42	0.52	0.85	0.96	-0.97	-0.8	-0.97		-0.97	0.96	-0.97	0.03	-0.22	-0.97	0.13	0.29	0.7	-0.15	-0.28	0.69	0.68	0.7	0.7
Ebitda	0.42	-0.45	-0.91	-0.97	1.0	0.86	1.0	-0.97		-0.98	1.0	0.08	0.21	1.0	-0.13	-0.45	-0.66	0.26	0.41	-0.79	-0.79	-0.66	-0.66
Total Operating Expenses	-0.4	0.52	0.97	1.0	-0.98	-0.79	-0.98	0.96	-0.98		-0.97	-0.04	-0.17	-0.97	0.1	0.4	0.71	-0.11	-0.28	0.84	0.85	0.71	0.71
Income Before Tax	0.46	-0.44	-0.9	-0.97	1.0	0.87	1.0	-0.97	1.0	-0.97		0.1	0.26	1.0	-0.18	-0.46	-0.65	0.27	0.42	-0.8	-0.78	-0.65	-0.65
Non Operating Income Net Other	0.62	0.79	-0.11	-0.03	0.07	0.11	0.07	0.03	0.08	-0.04	0.1		0.5	0.11	-0.47	-0.39	-0.05	0.14	0.19	-0.28	-0.14	-0.05	-0.05
Total Other Income Expense Net	0.92	0.21	-0.11	-0.17	0.21	0.47	0.21	-0.22	0.21	-0.17	0.26	0.5		0.28	-0.97	-0.51	0.18	0.53	0.56	-0.33	-0.14	0.18	0.18
Net Income	0.48	-0.44	-0.9	-0.97	1.0	0.88	1.0	-0.97	1.0	-0.97	1.0	0.11	0.28		-0.2	-0.48	-0.64	0.29	0.43	-0.8	-0.78	-0.64	-0.64
Income Tax Expense	-0.9	-0.22	0.06	0.1	-0.13	-0.37	-0.13	0.13	-0.13	0.1	-0.18	-0.47	-0.97	-0.2		0.47	-0.2	-0.53	-0.56	0.33	0.13	-0.2	-0.2
Net Interest Income	-0.46	0.0	0.46	0.39	-0.44	-0.77	-0.45	0.29	-0.45	0.4	-0.46	-0.39	-0.51	-0.48	0.47		-0.22	-0.7	-0.8	0.69	0.6	-0.22	-0.22
Discontinued Operations	-0.17	0.29	0.67	0.71	-0.66	-0.23	-0.66	0.7	-0.66	0.71	-0.65	-0.05	0.18	-0.64	-0.2	-0.22		0.37	0.24	0.44	0.49	1.0	1.0
Total Revenue	0.35	0.01	-0.06	-0.11	0.25	0.63	0.26	-0.15	0.26	-0.11	0.27	0.14	0.53	0.29	-0.53	-0.7	0.37		0.98	-0.27	-0.17	0.37	0.37
Gross Profit	0.44	-0.06	-0.25	-0.28	0.4	0.74	0.4	-0.28	0.41	-0.28	0.42	0.19	0.56	0.43	-0.56	-0.8	0.24	0.98		-0.46	-0.37	0.24	0.24
Cost Of Revenue	-0.52	0.33	0.92	0.84	-0.79	-0.75	-0.79	0.69	-0.79	0.84	-0.8	-0.28	-0.33	-0.8	0.33	0.69	0.44	-0.27	-0.46		0.97	0.44	0.44
Reconciled Depreciation	-0.35	0.45	0.94	0.85	-0.78	-0.69	-0.79	0.68	-0.79	0.85	-0.78	-0.14	-0.14	-0.78	0.13	0.6	0.49	-0.17	-0.37	0.97		0.49	0.49
Extraordinary Items	-0.17	0.29	0.67	0.71	-0.66	-0.23	-0.66	0.7	-0.66	0.71	-0.65	-0.05	0.18	-0.64	-0.2	-0.22	1.0	0.37	0.24	0.44	0.49		1.0
Selling And Marketing Expenses	-0.17	0.29	0.67	0.71	-0.66	-0.23	-0.66	0.7	-0.66	0.71	-0.65	-0.05	0.18	-0.64	-0.2	-0.22	1.0	0.37	0.24	0.44	0.49	1.0

Click cells to compare fundamentals

Salarius Pharmaceuticals Account Relationship Matchups

Salarius Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Income	292.0K	152.0K	1.3M	218.7K	355.8K	441.7K
Depreciation And Amortization	127.4K	18.1K	19.2K	6.7K	10.1K	9.5K
Selling General Administrative	7.7M	6.1M	6.1M	7.1M	5.7K	5.4K
Other Operating Expenses	11.7M	12.8M	14.7M	23.0M	12.9K	12.2K
Operating Income	(9.6M)	(7.8M)	(12.8M)	(31.8M)	(12.9K)	(13.5K)
Net Income From Continuing Ops	(6.9M)	(7.4M)	(12.8M)	(31.6M)	(18.0M)	(18.9M)
Ebit	(9.6M)	(7.3M)	(12.8M)	(31.6M)	(12.9K)	(13.5K)
Research Development	4.0M	6.9M	8.5M	15.8M	7.2K	6.8K
Ebitda	(9.4M)	(7.3M)	(12.7M)	(31.6M)	(2.8K)	(3.0K)
Total Operating Expenses	11.7M	12.8M	14.7M	23.0M	12.9K	12.2K
Income Before Tax	(6.9M)	(7.4M)	(12.8M)	(31.6M)	(12.5K)	(13.2K)
Total Other Income Expense Net	2.6M	434.1K	44.7K	233.2K	352.25	334.64
Net Income Applicable To Common Shares	(6.9M)	(7.7M)	(12.8M)	(31.6M)	(28.4M)	(27.0M)
Net Income	(5.6M)	(7.1M)	(12.7M)	(31.4M)	(12.5K)	(13.2K)
Income Tax Expense	(1.3M)	(255.5K)	(63.9K)	(233.2K)	(1.0)	(1.05)
Net Interest Income	15.6K	(3.0K)	(3.3K)	218.7K	355.8K	373.6K
Total Revenue	1.3M	838K	3.5M	5.2M	1.8M	0.0
Gross Profit	3.5M	5.2M	1.8M	(6.7K)	(10.1K)	(9.5K)
Cost Of Revenue	4.0K	6.9K	19.2K	6.7K	10.1K	9.5K
Reconciled Depreciation	127.4K	18.1K	19.2K	6.7K	10.6K	10.1K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Salarius Stock Analysis

When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Salarius Historical Income Statement

About Salarius Income Statement Analysis

Salarius Pharmaceuticals Income Statement Chart

Total Operating Expenses

Income Before Tax

Salarius Pharmaceuticals income statement Correlations

Salarius Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Salarius Pharmaceuticals income statement Accounts

Also Currently Popular

Additional Tools for Salarius Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Interest Income	Depreciation And Amortization
Interest Expense	Selling General Administrative
Other Operating Expenses	Operating Income
Net Income From Continuing Ops	Ebit
Research Development	Ebitda
Total Operating Expenses	Income Before Tax
Non Operating Income Net Other	Total Other Income Expense Net
Net Income Applicable To Common Shares	Net Income
Income Tax Expense	Net Interest Income
Discontinued Operations	Total Revenue
Gross Profit	Cost Of Revenue
Reconciled Depreciation	Extraordinary Items
Selling And Marketing Expenses

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit

Total Operating Expenses	- 0.98	Ebitda
Total Operating Expenses	- 0.98	Ebit
Total Operating Expenses	- 0.98	Operating Income
Ebit	- 0.98	Other Operating Expenses
Operating Income	- 0.98	Other Operating Expenses
Income Tax Expense	- 0.97	Total Other Income Expense Net